Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery
A Prospective Randomized Study to Assess the Efficacy and Safety of Bolus-dose Lusedra (Fospropofol Disodium) 6.5 mg/kg or 10 mg/kg Versus a Placebo (With Midazolam Rescue) for Minimal-to-moderate Sedation in Patients Undergoing Procedural Sedation for Regional Anesthesia Blocks Prior to Orthopedic Surgery
Sponsor: Eisai Inc.
Terminated
Funding terminated by funding source.
Other terminated trials from Eisai Inc.
- Recurrent Hepatocellular Carcinoma · May 2025
- Epilepsies, Myoclonic · Phase PHASE3 · Aug 2024
- Catamenial Epilepsy · Phase PHASE4 · Dec 2023
- Epilepsy · Phase PHASE4 · May 2023
- Amyotrophic Lateral Sclerosis · Phase NA · Feb 2023
More terminations from Eisai Inc.
Listed as NCT01195103, this PHASE4 trial focuses on Orthopedic Surgery and Procedural Sedation and remains terminated or withdrawn. Sponsored by Eisai Inc., it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
Feb 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eisai Inc.
- Mayo Clinic
For direct contact, visit the study record on ClinicalTrials.gov .